About: Vero cell upstream bioprocess development for the production of viral vectors and vaccines

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Vero cell upstream bioprocess development for the production of viral vectors and vaccines Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Vero cell upstream bioprocess development for the production of viral vectors and vaccines
Creator	Kamen, Amine Kiesslich, Sascha
source	Elsevier; Medline; PMC
abstract	The Vero cell line is considered the most used continuous cell line for the production of viral vectors and vaccines. Historically, it is the first cell line that was approved by the WHO for the production of human vaccines. Comprehensive experimental data on the production of many viruses using the Vero cell line can be found in the literature. However, the vast majority of these processes is relying on the microcarrier technology. While this system is established for the large-scale manufacturing of viral vaccine, it is still quite complex and labor intensive. Moreover, scale-up remains difficult and is limited by the surface area given by the carriers. To overcome these and other drawbacks and to establish more efficient manufacturing processes, it is a priority to further develop the Vero cell platform by applying novel bioprocess technologies. Especially in times like the current COVID-19 pandemic, advanced and scalable platform technologies could provide more efficient and cost-effective solutions to meet the global vaccine demand. Herein, we review the prevailing literature on Vero cell bioprocess development for the production of viral vectors and vaccines with the aim to assess the recent advances in bioprocess development. We critically underline the need for further research activities and describe bottlenecks to improve the Vero cell platform by taking advantage of recent developments in the cell culture engineering field.
has issue date	2020-08-05(xsd:dateTime)
bibo:doi	10.1016/j.biotechadv.2020.107608
bibo:pmid	32768520
has license	no-cc
sha1sum (hex)	950fce71614d47c71185b5fe954622271cecbe94
schema:url	https://doi.org/10.1016/j.biotechadv.2020.107608
resource representing a document's title	Vero cell upstream bioprocess development for the production of viral vectors and vaccines
has PubMed Central identifier	PMC7405825
has PubMed identifier	32768520
schema:publication	Biotechnol Adv
resource representing a document's body	covid:950fce71614d47c71185b5fe954622271cecbe94#body_text
is schema:about of	named entity 'A.A.' named entity 'viral vectors' named entity 'VIRAL VECTORS' named entity 'ARTICLE' named entity 'VACCINES' covid:arg/950fce71614d47c71185b5fe954622271cecbe94 named entity 'Vero' named entity 'article' named entity 'viral vectors' named entity 'Vero' named entity 'viral vectors' named entity 'vaccines' named entity 'vaccines' named entity 'mammalian cells' named entity 'shear stress' named entity 'Vero' named entity 'Flaviviridae' named entity 'Vero cell' named entity 'measles virus' named entity 'Vero cell line' named entity '5.5' named entity 'virus' named entity 'Vero' named entity 'cation' named entity 'microcarrier' named entity 'rabies virus' named entity 'media components' named entity 'bioreactor' named entity 'cell growth' named entity 'cell growth' named entity 'microcarrier' named entity 'Yellow fever' named entity 'Vero cell' named entity 'Yellow fever virus' named entity 'ammonia' named entity 'Vero cell' named entity 'enterovirus' named entity 'bioreactor' named entity 'animal cell' named entity 'MOI' named entity 'Herpes simplex virus' named entity 'omics' named entity 'HeLa' named entity 'Grein' named entity 'poliovirus' named entity 'Vero' named entity 'serum' named entity 'cell growth' named entity 'cell growth' named entity 'Vero' named entity 'Herpesviridae' named entity 'MOI' named entity 'host cell's' named entity 'cellular energy' named entity 'Orthopneumovirus' named entity 'multiplicity of infection' named entity 'batch mode' named entity 'genetic engineering' named entity 'HEK293' named entity 'Grein' named entity 'Vero' named entity 'cell growth' named entity 'Rourou' named entity 'JEV' named entity 'bioreactor' named entity 'virus' named entity 'genome' named entity 'Vero' named entity 'cell-based vaccines' named entity 'dissolved oxygen' named entity 'cell metabolism' named entity 'vaccine' named entity 'Paramyxoviridae' named entity 'infection' named entity 'virus infection' named entity 'type II' named entity 'Vero cells' named entity 'infection' named entity 'Rhim' named entity 'virus'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software